Back to Search Start Over

Follistatin-like protein 1 sustains colon cancer cell growth and survival

Authors :
Carmine Stolfi
Flavio Caprioli
Angela Ortenzi
Eleonora Franzè
Piero Rossi
Federica Facciotti
Silvia Sedda
Vincenzo Dinallo
Giovanni Monteleone
Antonio Di Grazia
Gerolamo Bevivino
Alfredo Colantoni
Bevivino, G
Sedda, S
Franzè, E
Stolfi, C
Di Grazia, A
Dinallo, V
Caprioli, F
Facciotti, F
Colantoni, A
Ortenzi, A
Rossi, P
Monteleone, G
Source :
Oncotarget
Publication Year :
2018
Publisher :
Impact Journals, LLC, 2018.

Abstract

Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein, which controls several physiological and pathological events. FSTL1 expression is deregulated in many tumors, but its contribution to colon carcinogenesis is not fully understood. Here, we investigated the expression and functional role of FSTL1 in colorectal cancer (CRC). A significant increase of FSTL1 was seen in human CRC as compared to the surrounding non-tumor tissues and this occurred at both RNA and protein level. Knockdown of FSTL1 in CRC cells with a specific antisense oligonucleotide (AS) reduced expression of regulators of the late G1 phase, such as phosphorylated retinoblastoma protein, E2F-1, cyclin E and phospho-cyclin-dependent kinase-2, and promoted accumulation of cells in the G1 phase of the cell cycle thus resulting in diminished cell proliferation. Consistently, recombinant FSTL1 induced proliferation of normal intestinal epithelial cells through an ERK1/2-dependent mechanism. Cell cycle arrest driven by FSTL1 AS in CRC cells was accompanied by activation of caspases and subsequent induction of apoptosis. Moreover, FSTL1 knockdown made CRC cells more susceptible to oxaliplatin and irinotecan-induced death. Data indicate that FSTL1 is over-expressed in human CRC and suggest a role for this protein in favouring intestinal tumorigenesis.

Details

ISSN :
19492553
Volume :
9
Database :
OpenAIRE
Journal :
Oncotarget
Accession number :
edsair.doi.dedup.....1b638f826c3c85fceaa606138c8ad6d2
Full Text :
https://doi.org/10.18632/oncotarget.25811